SCHEMBL5743368

SCHEMBL5743368

O=[N+]([O-])c1ccc(N2CCN(CCCO)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.61
SIRT6 Q8N6T7 1/20 0.60
KMT2A Q03164 1/20 0.58
MAPT P10636 3/20 0.57
LMNA P02545 2/20 0.57
MAPK1 P28482 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ESRRG P62508 1/20 0.57
POLB P06746 3/20 0.56
KCNJ1 P48048 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9436570 0.94 HTR1A (0.58) HTR1ASIRT6KMT2AMAPTLMNA
SCHEMBL6151796 0.91 SIRT6 (0.64) HTR1ASIRT6KMT2AMAPTLMNA
SCHEMBL2717022 0.91 SIRT6 (0.64) HTR1ASIRT6KMT2AMAPTLMNA
SCHEMBL5206660 0.86 LMNA (0.63) HTR1ASIRT6KMT2AMAPTLMNA
SCHEMBL6945690 0.85 SIRT6 (0.65) HTR1ASIRT6KMT2AMAPTLMNA
SCHEMBL5187796 0.85 SIRT6 (0.60) HTR1ASIRT6KMT2AMAPTLMNA
SCHEMBL5780433 0.85 KMT2A (0.58) HTR1ASIRT6KMT2AMAPTLMNA
SCHEMBL3187189 0.85 HTR1A (0.64) HTR1ASIRT6KMT2AMAPTLMNA
SCHEMBL7127825 0.85 HTR1A (0.67) HTR1ASIRT6KMT2AMAPTLMNA
SCHEMBL918272 0.85 HTR1A (0.57) HTR1ASIRT6KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100482651-C Diaminothiazoles HOFFMANN LA ROCHE (CH) 2009-04-29 CN disclosed
US-7105670-B2 Intermediates useful in the preparation of diaminothiazoles HOFFMANN-LA ROCHE INC. (US) 2006-09-12 US disclosed
US-7094896-B2 Diaminothiazoles having antiproliferative activity HOFFMANN-LA ROCHE INC. (US) 2006-08-22 US disclosed
EP-1358169-B1 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE HOFFMANN LA ROCHE (CH) 2006-01-11 EP disclosed
US-6756374-B2 CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS HOFFMANN-LA ROCHE INC. 2004-06-29 US disclosed
US-20040087594-A1 Diaminothiazoles having antiproliferative activity DING QINGJIE (US) 2004-05-06 US disclosed
US-20040082595-A1 Intermediates useful in the preparation of diaminothiazoles DING QINGJIE (US) 2004-04-29 US disclosed
CN-1487927-A Diaminothiazoles - 2004-04-07 CN disclosed
EP-1358169-A2 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE F. HOFFMANN-LA ROCHE AG (CH) 2003-11-05 EP disclosed
US-20020151554-A1 Diaminothiazoles having antiproliferative activity CHEN LI (US) 2002-10-17 US disclosed
WO-2002057261-A2 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE F. HOFFMANN-LA ROCHE AG (CH) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087594-A1 Diaminothiazoles having antiproliferative activity CDK4, CDK2, CDKL4 HTR1A 3617/4885SIRT6 732/4885KMT2A 634/4885
US-20020151554-A1 Diaminothiazoles having antiproliferative activity CDK4, CDK2, CDKL4 HTR1A 3617/4885SIRT6 732/4885KMT2A 634/4885
US-20040082595-A1 Intermediates useful in the preparation of diaminothiazoles CDK4, CDK2, CDKL4 HTR1A 3774/4885SIRT6 612/4885KMT2A 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.